CalciMedica (CALC) CEO awarded 148,482 stock options at $0.585
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share. The options expire on April 4, 2036.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until a Form S-8 is filed for shares automatically added to the company’s 2023 Equity Incentive Plan on January 1, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Leheny A. Rachel
Role
CHIEF EXECUTIVE OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 148,482 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 148,482 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 148,482 options
Exercise price: $0.585 per share
Total derivatives after grant: 148,482 options
+3 more
6 metrics
Option grant size
148,482 options
Employee Stock Option grant to CEO Rachel A. Leheny
Exercise price
$0.585 per share
Exercise price for the employee stock options
Total derivatives after grant
148,482 options
Total derivative securities following transaction
Expiration date
April 4, 2036
Option expiration for the granted stock options
Vesting commencement
April 1, 2026
Start date for monthly vesting installments
Vesting rate
1/48th monthly
Vesting schedule over four years
Key Terms
Employee Stock Option (Right to Buy), Equity Incentive Plan, evergreen provision, Form S-8, +1 more
5 terms
Employee Stock Option (Right to Buy) financial
"security_title: "Employee Stock Option (Right to Buy)""
Equity Incentive Plan financial
"under the Company's 2023 Equity Incentive Plan on January 1, 2026"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
evergreen provision financial
"pursuant to an annual "evergreen" provision"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
Form S-8 regulatory
"until the filing of the Company's registration statement on Form S-8"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
vesting financial
"1/48th of the shares subject to the option vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did CalciMedica (CALC) report in this Form 4?
CalciMedica reported a stock option grant to CEO and director Rachel A. Leheny for 148,482 options. These options give her the right to buy common stock at a fixed price, serving as equity-based compensation tied to the company’s future performance.
How many stock options did CalciMedica CEO Rachel Leheny receive?
Rachel Leheny received 148,482 employee stock options. Each option allows her to purchase one share of CalciMedica common stock. The grant represents a single equity award and is reflected as 148,482 derivative securities following the reported transaction.
What is the exercise price of the CalciMedica stock options granted?
The granted options have an exercise price of $0.585 per share. This means Rachel Leheny can purchase CalciMedica common stock at $0.585 if the options vest and are exercised before expiration, regardless of the future market price at that time.
When do Rachel Leheny’s CalciMedica options start vesting and on what schedule?
Vesting for the options begins on April 1, 2026. From that date, 1/48th of the 148,482 options vest monthly over four years, creating a gradual vesting schedule that links full ownership of the award to continued service over time.
Are there conditions that must be met before any of the CalciMedica options vest?
Yes. No shares will vest until CalciMedica files a Form S-8 covering shares automatically added on January 1, 2026, to the 2023 Equity Incentive Plan under its evergreen provision, creating a regulatory prerequisite before vesting can begin.
When do the newly granted CalciMedica stock options expire?
The options granted to Rachel Leheny expire on April 4, 2036. She may exercise vested options any time up to that expiration date, subject to plan terms and other applicable restrictions governing option exercises and insider trading compliance.